In a report issued on June 27, Michael Matson from Needham reiterated a Buy rating on Boston Scientific Corp (BSX), with a price target of $46. The company’s shares closed on Friday at $42.98, close to its 52-week high of $43.02.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 9.6% and a 65.3% success rate. Matson covers the Healthcare sector, focusing on stocks such as Cardiovascular Systems, Zimmer Biomet Holdings, and Merit Medical Systems.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Boston Scientific Corp with a $45.68 average price target, a 6.3% upside from current levels. In a report issued on June 14, UBS also maintained a Buy rating on the stock with a $47 price target.
See today’s analyst top recommended stocks >>
Based on Boston Scientific Corp’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $2.49 billion and net profit of $424 million. In comparison, last year the company earned revenue of $2.38 billion and had a net profit of $298 million.
Based on the recent corporate insider activity of 161 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Cardiovascular, Rhythm Management, and MedSurg.
